resourceId,resourceName,resourceType,observationText,observationType,observationPhase,observationTime,observationTimeUnits,doi
98e86631-5d93-4b4a-862a-d2758420674a,Cnp-EGFR (deltaPten/C-EGFR),['Animal Model'],"Mice with biallelic Pten inactivation and EGFR overexpression in Schwann cells (deltaPten/C-EGFR) had a median survival of only 26 days, significantly shorter than control cohorts with one Pten allele intact (Pten-het/C-EGFR, median survival 415 days) or without EGFR overexpression (deltaPten, median survival 247 days).","['Survival', 'Disease progression']",postnatal,26,days,https://doi.org/10.1155/2012/620834
98e86631-5d93-4b4a-862a-d2758420674a,Cnp-EGFR (deltaPten/C-EGFR),['Animal Model'],"The deltaPten/C-EGFR mice developed enlarged peripheral nerves including brachial plexus (100%), trigeminal nerves (92%), lumbar sacral plexus (50%), and sciatic nerves (50%), as well as multiple enlarged dorsal root ganglia.","['Tumor incidence', 'Tumor location']",postnatal,,,https://doi.org/10.1155/2012/620834
98e86631-5d93-4b4a-862a-d2758420674a,Cnp-EGFR (deltaPten/C-EGFR),['Animal Model'],"The deltaPten/C-EGFR mice had significantly more enlarged dorsal root ganglia compared to deltaPten or Pten-het/C-EGFR control cohorts, indicating Pten loss contributed to this phenotype when combined with EGFR overexpression.",['Tumor incidence'],postnatal,,,https://doi.org/10.1155/2012/620834
98e86631-5d93-4b4a-862a-d2758420674a,Cnp-EGFR (deltaPten/C-EGFR),['Animal Model'],The enlarged peripheral nerves from deltaPten/C-EGFR mice were classified as high-grade peripheral nerve sheath tumors (PNSTs) based on histological analysis.,['Tumor grade'],postnatal,,,https://doi.org/10.1155/2012/620834
98e86631-5d93-4b4a-862a-d2758420674a,Cnp-EGFR (deltaPten/C-EGFR),['Animal Model'],The deltaPten/C-EGFR mice exhibited paralysis prior to being euthanized when moribund.,['Neurological symptoms'],postnatal,,,https://doi.org/10.1155/2012/620834
98e86631-5d93-4b4a-862a-d2758420674a,Cnp-EGFR (deltaPten/C-EGFR),['Animal Model'],"Treatment of deltaPten/C-EGFR mice with the EGFR inhibitor cetuximab from birth to 6 weeks of age was able to reverse the phenotype, with no significant differences remaining compared to wild-type mice in measures like nerve area, nuclei number, and mast cell number.",['Drug response'],postnatal,6,weeks,https://doi.org/10.2353/ajpath.2006.050859
